Zanubrutinib in the Treatment of Recurrent Refractory Mantle Cell Lymphoma

NCT05486013 · clinicaltrials.gov ↗
UNKNOWN
Status
30
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

Peking University Third Hospital

Collaborators